Article Details
Retrieved on: 2021-08-24 09:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities assumed coverage on Iovance Biotherapeutics in a research report on Monday, May 3rd. They set a "buy" rating and a $50.00 price objective ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here